Back to Journals » International Journal of Nanomedicine » Volume 12

In vitro study on anti-inflammatory effects of epigallocatechin-3-gallate-loaded nano- and microscale particles

Authors Wu YR, Choi HJ, Kang YG, Kim JK, Shin JW

Received 13 July 2017

Accepted for publication 17 August 2017

Published 22 September 2017 Volume 2017:12 Pages 7007—7013


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Thomas Webster

Yan Ru Wu,1,* Hong Jin Choi,2,* Yun Gyeong Kang,2 Jeong Koo Kim,1,2 Jung-Woog Shin1–3

1Department of Health Science and Technology, Inje University, Gimhae, Gyeongnam, Republic of Korea; 2Department of Biomedical Engineering, Inje University, Gimhae, Gyeongnam, Republic of Korea; 3Cardiovascular and Metabolic Disease Center, Institute of Aged Life Redesign, UHARC, Inje University, Gimhae, Gyeongnam, Republic of Korea

*These authors contributed equally to this work

Purpose: This study aimed to develop an anti-inflammation system consisting of epigallocatechin-3-gallate (EGCG) encapsulated in poly(lactide-co-glycolic acid) (PLGA) particles to promote wound healing.
Methods: Nano- and microscale PLGA particles were fabricated using a water/oil/water emulsion solvent evaporation method. The optimal particle size was determined based on drug delivery efficiency and biocompatibility. The particles were loaded with EGCG. The anti-inflammatory effects of the particles were evaluated in an in vitro cell-based inflammation model.
Results: Nano- and microscale PLGA particles were produced. The microscale particles showed better biocompatibility than the nanoscale particles. In addition, the microscale particles released ~60% of the loaded drug, while the nanoscale particles released ~50%, within 48 hours. Thus, microscale particles were selected as the carriers. The optimal EGCG working concentration was determined based on the effects on cell viability and inflammation. A high EGCG dose (100 µM) resulted in poor cell viability; therefore, a lower dose (≤50 µM) was used. Moreover, 50 µM EGCG had a greater anti-inflammatory effect than 10 µM concentration on lipopolysaccharide-induced inflammation. Therefore, 50 µM EGCG was selected as the working dose. EGCG-loaded microparticles inhibited inflammation in human dermal fibroblasts. Interestingly, the inhibitory effects persisted after replacement of the drug-loaded particle suspension solution with fresh medium.
Conclusion: The EGCG-loaded microscale particles are biocompatible and exert a sustained anti-inflammatory effect.

Keywords: wound healing, anti-inflammation, EGCG, microparticles, carriers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]